EUVIMEDEUVIMED entdecken
Crossref

Utility of an anchored multiplex polymerase chain reaction‐based fusion assay for diagnosis of soft tissue tumors in cytology

T Leif Helland, Adam S Fisch iD, Ivan Chebib iD

Cancer Cytopathology · 2024

DOI: 10.1002/cncy.22881 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cytopathology, 2024. Verfasst von T Leif Helland und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Multiplex Polymerase Chain Reaction, Soft Tissue Neoplasms, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fine‐needle aspiration specimens from soft tissue tumors are complicated by lack of tissue architecture and limited material for ancillary testing. There are little data on the feasibility of next‐generation sequencing techniques for fusion detection on soft tissue cytology specimens. This study explored the role of an anchored multiplex polymerase chain reaction (PCR)‐based gene fusion assay in aiding the diagnosis of mesenchymal neoplasms on cytology samples.

Methods

The laboratory information system was queried for cytology specimens that had undergone testing by anchored multiplex PCR. After exclusion of epithelial and hematolymphoid neoplasms, clinical and pathologic information was collected on the remaining cases.

Results

There were 1609 cytology specimens tested with anchored multiplex PCR. Of these, 48 (3%) were cytology specimens from mesenchymal tumors. Anchored multiplex PCR was positive for a reportable fusion transcript in 14 of 48 cases (29%); there was no fusion detected in 32 cases (67%), and there was insufficient tissue for analysis in two cases (4%). The detectable fusion partners included ALK ( n = 4), STAT6 ( n = 4), EWSR1 ( n = 3), and one each of SS18 , YAP1 , and PHF1 . Of the cases in which a fusion partner was detected, eight of 14 were disease‐defining on cytology preparation, and six of 14 provided molecular confirmation of a metastatic focus of a previously diagnosed tumor.

Conclusions

The anchored, multiplex PCR‐based gene fusion assay is a powerful orthogonal tool in helping diagnose mesenchymal neoplasms on cytology specimens. The material obtained for cytologic analysis yields sufficient quality/quantity of tissue in the majority of cases tested.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiplex Polymerase Chain ReactionSoft Tissue NeoplasmsOncogene Proteins, FusionHumansFemaleMaleAdultMiddle AgedBiopsy, Fine-NeedleAgedCytodiagnosisYoung AdultAdolescentBiomarkers, TumorHigh-Throughput Nucleotide SequencingChildAged, 80 and over

Stichwörter der Autor:innen

cytologyfine‐needle aspiration (FNA)fusionpolymerase chain reaction (PCR)sarcomasoft tissue

Substanzen

Oncogene Proteins, FusionBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Mass General Brigham and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Adam S Fisch, Ivan Chebib

Zitieren

APA

Helland, T. L., Fisch, A. S., & Chebib, I. (2024). Utility of an anchored multiplex polymerase chain reaction‐based fusion assay for diagnosis of soft tissue tumors in cytology. Cancer Cytopathology. https://doi.org/10.1002/cncy.22881

Vancouver

Helland TL, Fisch AS, Chebib I. Utility of an anchored multiplex polymerase chain reaction‐based fusion assay for diagnosis of soft tissue tumors in cytology. Cancer Cytopathology. 2024. doi:10.1002/cncy.22881

BibTeX
@article{Helland2024,
  author = {Helland, T Leif and Fisch, Adam S and Chebib, Ivan},
  title = {Utility of an anchored multiplex polymerase chain reaction‐based fusion assay for diagnosis of soft tissue tumors in cytology},
  journal = {Cancer Cytopathology},
  year = {2024},
  doi = {10.1002/cncy.22881}
}
Kostenlos starten →